Mersana Therapeutics (MRSN) Stock Forecast, Price Target & Predictions
MRSN Stock Forecast
Mersana Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a 35.14% upside from MRSN’s last price of $2.22) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
MRSN Price Target
MRSN Analyst Ratings
Buy
Mersana Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 14, 2024 | Collen Kusy | Robert W. Baird | $3.00 | $1.35 | 122.22% | 35.14% |
10
Mersana Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $3.00 |
Last Closing Price | $2.22 | $2.22 | $2.22 |
Upside/Downside | -100.00% | -100.00% | 35.14% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 15, 2024 | Citigroup | Buy | Buy | Initialise |
Feb 29, 2024 | Guggenheim | Underperform | Underperform | Hold |
Feb 29, 2024 | Wedbush | Buy | Buy | Hold |
Feb 29, 2024 | Wedbush | - | Outperform | Upgrade |
Feb 28, 2024 | BTIG | - | Buy | Upgrade |
Dec 04, 2023 | Citigroup | - | Buy | Upgrade |
Jul 27, 2023 | Piper Sandler | - | Overweight | Initialise |
Jul 27, 2023 | Scotiabank | - | Sector Outperform | Initialise |
Jun 15, 2023 | Guggenheim | - | Buy | Initialise |
Feb 18, 2022 | SVB Leerink | Outperform | Outperform | Hold |
10
Mersana Therapeutics Financial Forecast
Mersana Therapeutics Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.70M | - | $10.65M | $7.80M | $14.69M | $5.57M | $4.28M | $2.04M | $11.00K | $11.00K | $11.00K | $11.00K | $11.00K | $11.00K | $796.00K | $11.00K | $42.00K | $844.00K |
Avg Forecast | $9.08M | $9.42M | $9.76M | $10.13M | $6.09M | $6.05M | $6.01M | $5.90M | $7.64M | $7.53M | $8.72M | $8.50M | $14.74M | $9.60M | $12.93M | $14.00M | $15.28M | $56.78M | $2.20M | $17.24M | $5.33K | $120.50K | $170.00K | $312.80K | $202.20K | $439.20K | $306.00K | $390.67K | $583.33K | $350.00K |
High Forecast | $13.86M | $14.37M | $14.90M | $15.45M | $9.30M | $9.24M | $9.18M | $9.00M | $15.40M | $11.49M | $8.72M | $12.97M | $29.54M | $9.75M | $19.73M | $21.36M | $23.32M | $56.78M | $2.20M | $17.24M | $5.33K | $120.50K | $170.00K | $312.80K | $202.20K | $439.20K | $306.00K | $390.67K | $583.33K | $350.00K |
Low Forecast | $3.67M | $3.81M | $3.95M | $4.10M | $2.47M | $2.45M | $2.43M | $2.39M | $1.44M | $3.05M | $8.72M | $3.44M | $7.12M | $9.45M | $5.23M | $5.66M | $6.18M | $56.78M | $2.20M | $17.24M | $5.33K | $120.50K | $170.00K | $312.80K | $202.20K | $439.20K | $306.00K | $390.67K | $583.33K | $350.00K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | - | 0.82% | 0.56% | 0.96% | 0.10% | 1.95% | 0.12% | 2.06% | 0.09% | 0.06% | 0.04% | 0.05% | 0.03% | 2.60% | 0.03% | 0.07% | 2.41% |
Forecast
Mersana Therapeutics EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-19.00M | - | $-54.31M | $-54.86M | $-45.83M | $-59.64M | $-51.23M | $-46.33M | $-47.79M | $-45.16M | $-40.61M | $-34.37M | $-28.49M | $-22.14M | $-19.45M | $-16.59M | $-15.88M | $-16.38M |
Avg Forecast | $-8.42M | $-8.73M | $-9.05M | $-9.39M | $-5.65M | $-5.61M | $-5.58M | $-5.47M | $-7.08M | $-6.98M | $-8.08M | $-34.46M | $-13.66M | $-8.90M | $-11.98M | $-36.85M | $-44.02M | $-52.97M | $-2.05M | $-39.41M | $-4.97K | $-112.40K | $-158.58K | $-24.68M | $-188.62K | $-409.69K | $-285.44K | $-17.49M | $-544.14K | $-326.49K |
High Forecast | $-3.41M | $-3.53M | $-3.66M | $-3.80M | $-2.29M | $-2.27M | $-2.26M | $-2.21M | $-1.33M | $-2.82M | $-8.08M | $-27.56M | $-6.60M | $-8.76M | $-4.85M | $-29.48M | $-35.21M | $-52.97M | $-2.05M | $-31.53M | $-4.97K | $-112.40K | $-158.58K | $-19.74M | $-188.62K | $-409.69K | $-285.44K | $-13.99M | $-544.14K | $-326.49K |
Low Forecast | $-12.84M | $-13.32M | $-13.81M | $-14.32M | $-8.62M | $-8.56M | $-8.51M | $-8.34M | $-14.27M | $-10.65M | $-8.08M | $-41.35M | $-27.38M | $-9.04M | $-18.29M | $-44.22M | $-52.82M | $-52.97M | $-2.05M | $-47.30M | $-4.97K | $-112.40K | $-158.58K | $-29.61M | $-188.62K | $-409.69K | $-285.44K | $-20.98M | $-544.14K | $-326.49K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.39% | - | 4.53% | 1.49% | 1.04% | 1.13% | 24.94% | 1.18% | 9608.16% | 401.77% | 256.10% | 1.39% | 151.05% | 54.04% | 68.15% | 0.95% | 29.18% | 50.16% |
Forecast
Mersana Therapeutics Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-18.56M | - | $-54.31M | $-57.15M | $-45.89M | $-60.69M | $-52.98M | $-47.98M | $-49.96M | $-45.47M | $-40.91M | $-34.69M | $-28.84M | $-22.49M | $-19.79M | $-16.93M | $-16.25M | $-16.79M |
Avg Forecast | $-21.06M | $-20.67M | $-20.65M | $-22.65M | $-21.84M | $-22.58M | $-22.83M | $-23.56M | $-18.36M | $-21.07M | $-20.46M | $-35.15M | $-19.66M | $-43.91M | $-53.56M | $-37.59M | $-45.12M | $484.61K | $-61.84M | $-40.20M | $-79.79M | $-69.01M | $-59.09M | $-24.91M | $-38.68M | $-37.03M | $-35.42M | $-17.84M | $-46.34M | $-45.33M |
High Forecast | $-4.76M | $-4.67M | $-4.67M | $-5.12M | $-4.94M | $-5.10M | $-5.16M | $-5.33M | $-12.96M | $-4.76M | $-4.63M | $-28.12M | $-13.76M | $-9.92M | $-12.10M | $-30.07M | $-36.09M | $484.61K | $-61.84M | $-32.16M | $-79.79M | $-69.01M | $-59.09M | $-19.93M | $-38.68M | $-37.03M | $-35.42M | $-14.27M | $-46.34M | $-45.33M |
Low Forecast | $-35.46M | $-34.80M | $-34.78M | $-38.15M | $-36.78M | $-38.02M | $-38.44M | $-39.67M | $-22.68M | $-35.47M | $-34.46M | $-42.18M | $-25.55M | $-73.94M | $-90.18M | $-45.11M | $-54.14M | $484.61K | $-61.84M | $-48.24M | $-79.79M | $-69.01M | $-59.09M | $-29.89M | $-38.68M | $-37.03M | $-35.42M | $-21.41M | $-46.34M | $-45.33M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | - | 1.01% | 1.52% | 1.02% | -125.24% | 0.86% | 1.19% | 0.63% | 0.66% | 0.69% | 1.39% | 0.75% | 0.61% | 0.56% | 0.95% | 0.35% | 0.37% |
Forecast
Mersana Therapeutics SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $10.13M | - | $18.19M | $18.33M | $14.80M | $14.57M | $14.80M | $12.78M | $10.67M | $10.12M | $8.88M | $7.21M | $5.91M | $5.88M | $5.17M | $4.94M | $4.21M | $4.44M |
Avg Forecast | $1.61B | $1.67B | $1.74B | $1.80B | $1.08B | $1.08B | $1.07B | $1.05B | $1.36B | $1.34B | $1.55B | $1.51B | $2.62B | $1.71B | $2.30B | $10.17M | $9.83M | $10.09B | $391.27M | $10.87M | $947.61K | $21.41M | $30.21M | $55.58M | $35.93M | $78.04M | $54.37M | $69.42M | $103.65M | $62.19M |
High Forecast | $2.46B | $2.55B | $2.65B | $2.75B | $1.65B | $1.64B | $1.63B | $1.60B | $2.74B | $2.04B | $1.55B | $2.31B | $5.25B | $1.73B | $3.51B | $12.20M | $11.80M | $10.09B | $391.27M | $13.05M | $947.61K | $21.41M | $30.21M | $55.58M | $35.93M | $78.04M | $54.37M | $69.42M | $103.65M | $62.19M |
Low Forecast | $652.80M | $677.00M | $702.09M | $728.11M | $438.10M | $435.28M | $432.48M | $424.04M | $255.70M | $541.26M | $1.55B | $611.33M | $1.26B | $1.68B | $929.67M | $8.13M | $7.86M | $10.09B | $391.27M | $8.70M | $947.61K | $21.41M | $30.21M | $55.58M | $35.93M | $78.04M | $54.37M | $69.42M | $103.65M | $62.19M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | - | 0.01% | 1.80% | 1.51% | 0.00% | 0.04% | 1.18% | 11.26% | 0.47% | 0.29% | 0.13% | 0.16% | 0.08% | 0.10% | 0.07% | 0.04% | 0.07% |
Forecast
Mersana Therapeutics EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 8 | 8 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.13 | - | $-0.47 | $-0.53 | $-0.45 | $-0.62 | $-0.55 | $-0.60 | $-0.69 | $-0.63 | $-0.59 | $-0.50 | $-0.42 | $-0.33 | $-0.33 | $-0.35 | $-0.34 | $-0.35 |
Avg Forecast | $-0.17 | $-0.17 | $-0.17 | $-0.18 | $-0.18 | $-0.18 | $-0.19 | $-0.19 | $-0.15 | $-0.17 | $-0.17 | $-0.18 | $-0.16 | $-0.36 | $-0.44 | $-0.43 | $-0.49 | - | $-0.51 | $-0.31 | $-0.66 | $-0.57 | $-0.49 | $-0.39 | $-0.32 | $-0.30 | $-0.29 | $-0.37 | $-0.38 | $-0.37 |
High Forecast | $-0.04 | $-0.04 | $-0.04 | $-0.04 | $-0.04 | $-0.04 | $-0.04 | $-0.04 | $-0.11 | $-0.04 | $-0.04 | $-0.04 | $-0.11 | $-0.08 | $-0.10 | $-0.10 | $-0.11 | - | $-0.51 | $-0.31 | $-0.66 | $-0.57 | $-0.49 | $-0.39 | $-0.32 | $-0.30 | $-0.29 | $-0.37 | $-0.38 | $-0.37 |
Low Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.31 | $-0.30 | $-0.31 | $-0.31 | $-0.32 | $-0.18 | $-0.29 | $-0.28 | $-0.30 | $-0.21 | $-0.60 | $-0.73 | $-0.72 | $-0.83 | - | $-0.51 | $-0.31 | $-0.66 | $-0.57 | $-0.49 | $-0.39 | $-0.32 | $-0.30 | $-0.29 | $-0.37 | $-0.38 | $-0.37 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | - | 1.08% | 1.24% | 0.91% | -155.35% | 1.08% | 1.94% | 1.05% | 1.11% | 1.21% | 1.27% | 1.32% | 1.08% | 1.13% | 0.95% | 0.89% | 0.94% |
Forecast
Mersana Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
RLAY | Relay Therapeutics | $4.66 | $19.40 | 316.31% | Buy |
PLRX | Pliant Therapeutics | $12.73 | $39.71 | 211.94% | Buy |
ABOS | Acumen Pharmaceuticals | $2.37 | $7.00 | 195.36% | Buy |
DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
RCUS | Arcus Biosciences | $14.62 | $33.00 | 125.72% | Buy |
REPL | Replimune Group | $11.23 | $24.20 | 115.49% | Buy |
SNDX | Syndax Pharmaceuticals | $15.95 | $34.30 | 115.05% | Buy |
VRDN | Viridian Therapeutics | $19.79 | $37.92 | 91.61% | Buy |
MRUS | Merus | $42.93 | $77.13 | 79.66% | Buy |
KURA | Kura Oncology | $15.91 | $26.00 | 63.42% | Buy |
MRSN | Mersana Therapeutics | $2.22 | $3.00 | 35.14% | Buy |
AMLX | Amylyx Pharmaceuticals | $5.23 | $6.67 | 27.53% | Buy |
PTGX | Protagonist Therapeutics | $40.65 | $50.00 | 23.00% | Buy |
HOOK | HOOKIPA Pharma | $2.72 | $3.00 | 10.29% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |